High Billing by Labs Continues to Be Trigger for Audits
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
Author Information
Danielle H. Tangorre
Danielle H. Tangorre, partner at Robinson+Cole, represents and advises a broad range of healthcare providers, including clinical laboratories and hospitals, on operational and compliance issues, federal and state fraud and abuse laws, other regulatory matters, and business transactions. Danielle completed a Clinical Ethics Fellowship at the Alden March Bioethics Institute at Albany Medical Center after obtaining an MS in Bioethics at Albany Medical Center, while concurrently completing law school at Albany Law School of Union University.
Posts by the Author